8-K - WGRX - Equibles

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM 8-K

CURRENT

REPORT

PURSUANT

TO SECTION 13 OR 15(d) OF THE

SECURITIES

EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): May 18, 2026

WELLGISTICS

HEALTH, INC.

(Exact name of registrant as specified in its charter)

Delaware	001-42530	93-3264234
(State<br> or other jurisdiction<br><br> <br>of<br> incorporation)	(Commission<br><br> <br>File<br> Number)	(IRS<br> Employer<br><br> <br>Identification<br> No.)

3000Bayport Drive

Suite950

Tampa,### FL 33607

(Address of principal executive offices, including zip code)

Registrant’s telephone number, including area code: (844) ### 203-6092

NotApplicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written<br> communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting<br> material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement<br> communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement<br> communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common<br> Stock, $0.0001 par value per share	WGRX	The Nasdaq Capital<br> Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item8.01 Other Events.

On May 18, 2026, Wellgistics Health, Inc. (the “Company”) filed correspondence with the Securities and Exchange Commission requesting withdrawal of the Company’s Preliminary Proxy Statement on Schedule 14A previously filed with the Securities and Exchange Commission on May 14, 2026, which superseded the Company’s previously filed proxy materials relating to a special meeting of stockholders.

The Company determined not to proceed with the preliminary proxy materials in their current form at this time as the Company continues to evaluate potential strategic transactions. The Company may file revised proxy materials with the Securities and Exchange Commission at a later date.

No definitive proxy materials relating to the withdrawn preliminary proxy statement were distributed or mailed to stockholders.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date:<br> May 18, 2026	WELLGISTICS HEALTH, INC.
	By:	/s/ Prashant Patel
		Prashant<br> Patel, President